Plant-Based
EXO NAD+
Korea's flagship all-in-one plant-based exosome skin rejuvenating solution with NAD+ complex.
View Product Plant-Based Skin Rejuvenation 5th Generation Multi-Active
LXC Lacto Exo Colla
A fifth-generation professional skin booster from CNB International Co., Ltd. (South Korea). LXC combines three distinct plant-origin exosome types — Lactobacillus, Panax Ginseng Callus, and Centella asiatica (CICA) — with H-PDRN from wild Alaskan salmon, atelocollagen, hydrolysed collagen, and a 7-peptide complex. Designed for MTS / microneedling-assisted delivery in professional aesthetic settings, with documented use for wrinkle reduction, hydration, elasticity, skin density, and pigmentation improvement.
Triple ExosomeLactobacillusGinsengCICAH-PDRN7 PeptidesAnti-PigmentationMTS
Product Overview
What Is LXC Lacto Exo Colla?
LXC Lacto Exo Colla is CNB International's fifth-generation skin booster. Its name maps directly to its three exosome sources and two collagen components: Lacto (Lactobacillus exosomes), Exo (exosomes — covering all three types), Colla (collagen: atelocollagen + hydrolysed collagen).
The product uses three plant-origin exosome types in a single lyophilised powder vial. This triple-exosome approach distinguishes LXC from single-source plant exosome products. Each exosome type carries a different active cargo profile — Lactobacillus for anti-ageing and pigmentation, Panax Ginseng Callus for collagen stimulation and UV protection, and CICA for regeneration and anti-inflammatory activity.
The solvent vial delivers H-PDRN (highly purified polydeoxyribonucleotide from wild Alaskan salmon), atelocollagen, hydrolysed collagen, 7 amino acid peptides including Acetyl Hexapeptide-8 and Palmitoyl Pentapeptide-4, tranexamic acid, and ascorbic acid. It is the most multi-active formulation in the plant-based range on Exosome Korea.
Regulatory note: LXC Lacto Exo Colla is a professional aesthetic product manufactured by CNB International Co., Ltd. It is not a pharmaceutical. It has not received FDA, EMA, or equivalent drug regulatory approval. There are currently no FDA-approved exosome products. Evidence maturity varies by active — H-PDRN and peptides have relatively established literature; exosome-specific evidence is emerging. For professional use only.
Generational Positioning in Korean Skin Boosters
Korean aesthetic manufacturers use generational numbering as a marketing framework to describe the evolution of skin booster formulations. It is not a formal scientific classification.
1
1st Generation — HA Skin Boosters
Hyaluronic acid only. Hydration and volume. Established evidence base.
2
2nd Generation — PDRN / PN
Polynucleotides added. Tissue repair and anti-inflammatory support alongside hydration.
3
3rd Generation — Growth Factors
EGF, FGF, and related actives added. Cellular signalling dimension introduced.
4
4th Generation — Exosomes
Single exosome type added to established actives. Emerging delivery and signalling vehicle.
5
5th Generation — Multi-Active Exosome Complex (LXC)
Multiple exosome types (triple complex) combined with H-PDRN, collagen, and peptides in a single MTS-optimised product. LXC's position.
This generational framework is CNB International's marketing positioning, not a regulatory or scientific standard. It is useful for contextualising LXC within the Korean professional skin booster landscape.
Three Exosome Sources — What Each Contributes
LXC's defining feature is its triple plant exosome complex. Each source is distinct — different botanical origin, different active cargo profile, different primary skin benefit.
LACTO
Lactobacillus Exosome
Exosomes derived from lactic acid bacteria. In LXC's formulation, Lactobacillus exosomes are positioned for anti-pigmentation activity, skin density improvement, and anti-ageing effects. Lactobacillus ferment lysate has an established record in topical cosmetics for microbiome and barrier associations. Its exosome form in an injectable professional product is an emerging application — evidence is preliminary relative to its topical use.
GINSENG
Panax Ginseng Callus Exosome
Exosomes from red ginseng callus cell culture. Panax Ginseng Callus Extracellular Vesicles are one of the more studied plant-origin exosome sources in Korean aesthetic formulations. Associated in the literature with collagen synthesis stimulation, skin renewal, bactericidal properties, and UV protection activity. Appears as a named INCI ingredient in several verified Korean professional skin boosters.
CICA
Centella asiatica (CICA) Exosome
Exosomes derived from Centella asiatica callus culture. CICA has one of the strongest evidence bases of any botanical in dermatology — associated with wound healing, anti-inflammatory activity, collagen synthesis, and skin cell regeneration. A 2025 peer-reviewed study in MDPI Cosmetics evaluated CICA-derived extracellular vesicles in a topical clinical setting, finding zero irritation in 30 participants and measurable improvements in skin density, hydration, and pore characteristics at two weeks.
Formulation
What's in Each Vial
LXC uses the same dual-vial MTS format as other CNB International products. Vial 1 contains the lyophilised exosome payload; Vial 2 is the active solvent that reconstitutes it and delivers additional therapeutic actives.
Vial No.1 — Freeze-Dried Exosome Ampoule (100 mg × 5 vials)
- •Lactobacillus Exosome — lactic acid bacteria-derived extracellular vesicles
- •Panax Ginseng Callus Extracellular Vesicles — red ginseng callus culture-derived
- •Centella asiatica (CICA) Callus Extracellular Vesicles — CICA plant-derived
- •Lyophilised format — freeze-dried powder preserving exosome bioactivity through storage
Vial No.2 — H-PDRN + Collagen + Peptides Solvent (6 ml × 5 vials)
- •H-PDRN — highly purified polydeoxyribonucleotide from wild Alaskan salmon; French manufacturer, European health authority authorised
- •Atelocollagen — purified collagen with low immunogenicity; structural and hydration support
- •Hydrolysed Collagen — for skin protein replenishment and moisture support
- •7 Amino Acid Peptides — including Acetyl Hexapeptide-8 (muscle-relaxing anti-wrinkle peptide) and Palmitoyl Pentapeptide-4 (Matrixyl — collagen synthesis stimulation)
- •Tranexamic Acid — pigmentation and uneven skin tone support
- •Ascorbic Acid (Vitamin C) — antioxidant and collagen synthesis co-factor
Formulation note: The above reflects publicly available CNB International product literature, verified reseller listings, and distributor documentation. Full INCI list and concentration data should be confirmed with manufacturer documentation before clinical use. Batch specifications may vary. Always reference official CNB International product documentation for the specific variant being sourced.
Protocol Context
How LXC Is Used — MTS Method
Step 1: Reconstitution
Open the aluminium cap and remove the rubber stopper from both ampoules. Inject Vial 2 (solvent) into Vial 1 (freeze-dried exosome powder). Shake well until the lyophilised powder is completely dissolved. Use immediately after mixing — do not store the reconstituted solution.
Step 2: First Application
Apply a sufficient amount of the reconstituted solution to clean skin. Wait 1–3 minutes to allow initial absorption before the MTS step.
Step 3: MTS Treatment
Apply MTS (Micro-Needle Therapy System) over the treated area. The needling drives the reconstituted solution through temporary microchannels into the skin. Depth should be adjusted to skin thickness and treatment area.
Step 4: Second Application
Apply the solution again after the MTS pass for additional topical coverage of the post-needling skin surface. Follow manufacturer protocol documentation for specific quantities and technique.
Treatment interval: once every 2 weeks per manufacturer guidance. LXC must not be applied to wounded skin, active eczema, or dermatitis. Administer in professional clinic settings by trained practitioners only. Compatible with needle-free impact technology as an alternative delivery method.
CLINICAL DATA CONTEXT
What CNB International's Research Shows
CNB International references clinical research data for LXC across their official trade listings and distributor documentation. The data covers outcomes at 4 weeks of use.
Eye Wrinkle Improvement
Significant improvement in eye wrinkle depth and appearance at 4 weeks, per CNB International clinical documentation.
Skin Moisturisation
Significant improvement in skin hydration levels at 4 weeks.
Skin Elasticity
Significant improvement in elasticity at 4 weeks.
Dermal Density
Significant improvement in dermal density at 4 weeks.
Pigmentation
Significant improvement in pigmentation at 4 weeks.
Data note: The clinical improvements cited above are from CNB International's own research documentation — they are not published peer-reviewed studies. This distinction matters. Do not present this data as independent clinical evidence on the product page. Describe it as manufacturer-reported internal data, and direct professional buyers to the manufacturer for full study methodology and documentation. This is the most defensible framing under both ethical and regulatory expectations.
Clinical Applications
Primary Use Cases
- •MTS / microneedling-assisted skin delivery
- •Fine line and wrinkle reduction protocols
- •Skin pigmentation and uneven tone
- •Deep hydration and skin density improvement
- •Skin elasticity and firmness support
- •Comprehensive multi-concern skin rejuvenation
Treatment Areas
- •Face — primary (incl. eye area)
- •Neck and décolleté
- •Hands
- •Body (per practitioner assessment)
Contraindications
Do not use LXC in the following situations, per CNB International manufacturer guidance:
- •Wounded or broken skin at the treatment site
- •Active eczema in the treatment area
- •Active dermatitis in the treatment area
- •Review additional contraindications with manufacturer documentation before clinical use
COMPARISON CONTEXT
LXC vs Other Products in the Range
LXC Lacto Exo Colla (This Product)
- •Triple plant exosome complex (Lacto + Ginseng + CICA)
- •CNB International — same manufacturer as Exotriple (Riola)
- •7 named peptides incl. Acetyl Hexapeptide-8 and Palmitoyl Pentapeptide-4
- •Tranexamic acid — pigmentation as a primary concern
- •MTS application protocol
- •Widest active coverage in the plant-based range
- •Anti-pigmentation as a documented primary outcome
EXO NAD+ (Comparison)
- •Triple plant exosome complex (Ginseng, CICA, Camellia)
- •Cherry Medi manufacturer
- •NAD+ coenzyme as distinguishing active
- •PDRN 30,000 ppm + PN 10,000 ppm in solvent
- •MTS and standalone skin booster use
- •No specific anti-pigmentation positioning
- •More vitality / radiance-focused
LXC (Plant-Based)
- •Triple plant exosome — no human-origin components
- •Lactobacillus exosome as distinguishing unique source
- •CICA exosome with emerging peer-reviewed clinical data
- •Anti-pigmentation as a specific documented outcome
ASCE+ SRLV (Human-Derived)
- •Human adipose stem cell exosomes (ExoCoBio)
- •Published peer-reviewed RCT data for skin + microneedling
- •Growth factor profile from human cell origin
- •Intradermal injection or post-needling topical use
Complete the Plant-Based Skin Range
Plant-Based
Exotriple (Riola)
CICA exosome + PDRN + atelocollagen dual-vial skin booster from CNB International's Riola brand for MTS workflows.
View Product
Plant-Based
EXOCODE Resilience - R
Rosa Damascena ExoCoBio exosome formulation targeting elasticity and firmness. ExoSCRT™ technology.
View ProductLXC Lacto Exo Colla Questions
It is a CNB International marketing framework positioning LXC within the evolution of Korean skin booster formulations — from HA (1st) through PDRN (2nd), growth factors (3rd), single exosomes (4th), to multi-exosome multi-active combinations (5th). It is not a formal scientific classification. LXC's 5th-generation claim reflects its triple exosome complex combined with H-PDRN, collagen, and 7 peptides in a single product.
LXC contains Lactobacillus exosomes, Panax Ginseng Callus exosomes, and Centella asiatica (CICA) exosomes. Lactobacillus exosomes are associated with anti-pigmentation and skin density. Ginseng callus exosomes are linked to collagen stimulation and UV protection. CICA exosomes carry anti-inflammatory and wound-healing properties with one of the stronger botanical evidence bases in dermatology. Each contributes a distinct active cargo profile to the overall formulation.
H-PDRN stands for Highly Purified PDRN — polydeoxyribonucleotide derived from wild Alaskan salmon and processed by a French manufacturer authorised by European health authorities. PDRN is one of the most evidence-established actives in Korean professional aesthetics, with published literature on tissue repair, skin hydration support, and anti-inflammatory activity. Its inclusion gives LXC an evidentially grounded anchor alongside the emerging exosome components.
Both. "Colla" refers to the collagen components in Vial 2: atelocollagen (a purified collagen with low immunogenicity) and hydrolysed collagen, plus a 7-peptide complex that includes peptides specifically associated with collagen and elastin synthesis — Acetyl Hexapeptide-8 and Palmitoyl Pentapeptide-4. The existing site page described "Colla" as "collagen-supporting peptides" only — that is partially accurate but omits the actual collagen proteins in the formulation.
Tranexamic acid is included in the solvent vial as a brightening and anti-pigmentation active. It is a well-documented ingredient in Korean professional aesthetics for its role in pigmentation management — inhibiting melanin synthesis pathways. This makes it consistent with LXC's documented positioning around anti-pigmentation as a primary outcome.
Both are made by CNB International. Exotriple (Riola brand) uses a single CICA exosome type, with a simpler formulation: CICA exosome + PDRN + atelocollagen/peptides. LXC adds Lactobacillus and Ginseng exosomes alongside CICA, extends the peptide list to 7 named peptides including Acetyl Hexapeptide-8, and adds tranexamic acid and ascorbic acid. LXC is the more complex, multi-concern product; Exotriple has a more focused CICA + PDRN profile.